Completed PHASE3 NCT00680914

Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™

Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A or Prevenar™ Co-administered With Hiberix™

Sponsor: GlaxoSmithKline

Conditions Infections, Streptococcal

Interventions GSK Biologicals' Hiberix™ Pneumococcal vaccine GSK1024850A (Synflorix) Prevenar

Updated 8 times since 2017 Last updated: May 9, 2018 Started: Jun 10, 2008 Primary completion: May 8, 2009 Completion: May 8, 2009

A PHASE3 clinical study on Infections, Streptococcal, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 8 data snapshots since 2008. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jul 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jul 2018 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline

Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ansan, South Korea , Bucheon-si, South Korea , Daejeon, South Korea , Gyeongnam, South Korea , Iksan, South Korea , Jeju City, South Korea , Jeonju Jeonbuk, South Korea , Pusan, South Korea , Seoul, South Korea , Suwon, South Korea and 1 more location